Oxidative Medicine and Cellular Longevity / 2016 / Article / Tab 1

Research Article

Serum Superoxide Dismutase Is Associated with Vascular Structure and Function in Hypertensive and Diabetic Patients

Table 1

Characteristics of study population.

All patientsDIA + HYPDIAHYPControl

Number307541618552
Age (years)54.76 ± 11.6960.75 ± 8.35 55.27 ± 12.8255.26 ± 10.9946.63 ± 12.54 <0.001
Male sex (, %)191 (62.21%)39 (72.22%)11 (68.75%)108 (58.38%)33 (63.46%)0.286
Superoxide dismutase (ng/mL)123.48 ± 57.20134.76 ± 63.60112.00 ± 35.23117.63 ± 47.69137.91 ± 82.680.079
8-Hydroxy-2-deoxyguanosine (ng/mL)6.97 ± 5.077.97 ± 5.526.24 ± 4.176.35 ± 5.137.40 ± 4.760.377
Systolic blood pressure (mmHg)138.26 ± 17.15142.59 ± 18.20119.31 ± 9.61143.66 ± 16.09126.26 ± 8.92<0.001
Diastolic blood pressure (mmHg)86.89 ± 10.9284.94 ± 12.0774.13 ± 5.1990.62 ± 9.8879.56 ± 6.66<0.001
Pulse pressure (mmHg)52.49 ± 12.37 57.37 ± 12.9245.39 ± 10.1553.16 ± 12.2346.91 ± 10.00<0.001
IMT medium average (mm)0.73 ± 0.110.80 ± 0.110.73 ± 0.120.73 ± 0.100.68 ± 0.14<0.001
IMT maximum average (mm)0.90 ± 0.140.98 ± 0.120.90 ± 0.150.90 ± 0.120.84 ± 0.17<0.001
Pulse wave velocity (m/s)8.98 ± 2.2210.39 ± 2.358.65 ± 2.279.00 ± 2.097.59 ± 1.61<0.001
Peripheral augmentation index92.76 ± 21.4395.85 ± 20.8788.94 ± 22.3495.15 ± 21.4582.22 ± 18.630.001
Central augmentation index30.31 ± 11.6631.35 ± 10.6730.44 ± 12.1031.81 ± 10.9423.85 ± 13.04<0.001
AASI38.25 ± 6.05 41.39 ± 5.9638.27 ± 5.4437.71 ± 5.8936.92 ± 5.96<0.001
D’Agostino cardiovascular risk19.73 ± 16.27 36.59 ± 18.2217.34 ± 11.8818.00 ± 13.728.59 ± 8.24<0.001
Smokers (, %)73 (23.77%)13 (24.07%)4 (25%)38 (20.54%)18 (34.62%)0.202
HDL (mg/dL)51.98 ± 12.4547.48 ± 9.7350.75 ± 12.6852.86 ± 12.6353.96 ± 13.420.023
LDL (mg/dL)125.91 ± 32.76108.13 ± 27.96108.50 ± 22.07132.71 ± 34.03125.75 ± 26.68<0.001
Total cholesterol (mg/dL)204.40 ± 36.98187.46 ± 34.70183.81 ± 23.66211.44 ± 37.58203.25 ± 32.77<0.001
Alcohol consumption (units/week)10.98 ± 20.2814.94 ± 21.353.69 ± 4.879.63 ± 15.8113.87 ± 32.150.111
HbA1c (%)5.41 ± 1.056.84 ± 1.406.68 ± 0.805.05 ± 0.464.83 ± 0.40<0.001
Glycemia (mg/dL)98.44 ± 30.44136.61 ± 46.27132.63 ± 32.6388.63 ± 11.1483.19 ± 8.75<0.001
Antihypertensive drugs (, %)143 (46.58%)48 (88.89%)0 (0.00%)95 (51.35%)0 (0.00%)<0.001
Antidiabetic drugs (, %)66 (21.50%)51 (94.44%)15 (93.75%)0 (0.00%)0 (0.00%)<0.001
Lipid-lowering drugs (, %)84 (27.36%)32 (59.26%)6 (37.50%)43 (23.24%)3 (5.77%)<0.001
Antiaggregants (, %)61 (19.87%)29 (53.70%)6 (37.50%)23 (12.43%)3 (5.77%)<0.001

Demographic, physical, and medical characteristics and drug therapies of patients included in the study. Data are expressed as mean ± standard deviation or percentage. AASI: ambulatory arterial stiffness index; DIA: diabetic nonhypertensive patients; DIA + HYP: diabetic hypertensive patients; HbA1c: glycosylated haemoglobin; HDL: cholesterol associated with high density lipoproteins; HYP: hypertensive patients; IMT: intima-media thickness; LDL: cholesterol associated with low density lipoproteins; : value, statistically significant differences (ANOVA).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.